<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04955899</url>
  </required_header>
  <id_info>
    <org_study_id>GAL1039</org_study_id>
    <nct_id>NCT04955899</nct_id>
  </id_info>
  <brief_title>Safety of Splenic Stimulation for RA</brief_title>
  <official_title>A Single Arm Pilot Study to Evaluate the Safety and Feasibility of Splenic Nerve Stimulation in Patients With Rheumatoid Arthritis Using an Active Implantable Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galvani Bioelectronics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NAMSA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Galvani Bioelectronics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of stimulating the splenic neurovascular&#xD;
      bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator,&#xD;
      external components and accessories. Participants eligible for implant will have active&#xD;
      rheumatoid arthritis (RA) and have an inadequate response or intolerance to at least two&#xD;
      biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) or JAK inhibitors (JAKis). Five&#xD;
      participants will be implanted with the device and receive neurostimulation for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be an open-label single-arm study to evaluate the safety and tolerability of&#xD;
      Galvani's neuromodulation system. Participants with active rheumatoid arthritis (RA) will be&#xD;
      implanted with the Galvani system and receive active stimulation for 12 weeks. The total&#xD;
      study duration in the study for each participant is approximately 5 months, with a 4-week&#xD;
      screening period, 4 weeks recovery from surgery and a 12-week 'treatment' period. The&#xD;
      participants will return to the clinic on pre-defined days for follow-up visits during the&#xD;
      trial period. At Days 42 and/or Day 56, if study participants are not responding to&#xD;
      stimulation, stimulation parameters might be adapted. At the end of the study (Day-84),&#xD;
      participants will enroll in a long-term follow-up study up to 5-years after enrollment in&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of the Galvani system</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence and relatedness of Adverse Events (AEs), which include clinically significant findings from Laboratory Safety Assessments (clinical chemistry and hematology), vital signs (blood pressure, heart rate, respiratory rate, and body temperature), and 12-Lead ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of stimulation on the change in pharmacodynamic and response biomarkers</measure>
    <time_frame>Day 1 to week 12</time_frame>
    <description>Changes from baseline (Day 1) in the levels of LPS-inducible cytokine/ chemokine release, in whole blood assay at different timepoints after start of stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the usability of the external Galvani System devices and accessories</measure>
    <time_frame>12 weeks</time_frame>
    <description>Summarize feedback collected on questionnaires pertaining to the use of the external Galvani System devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the participants' perception of therapy and sensation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Summarize feedback collected on questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate device performance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Tabulation of device deficiencies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Active Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active stimulation for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Stimulation</intervention_name>
    <description>The Galvani System will be implanted in eligible participants, and stimulation will be turned ON</description>
    <arm_group_label>Active Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult-onset RA of at least six months duration&#xD;
&#xD;
          -  Male or female participants, 22-75 years of age&#xD;
&#xD;
          -  Active RA&#xD;
&#xD;
          -  Inadequate Response to at least 2 biologic DMARDs and/or JAK- inhibitors (JAKis)&#xD;
&#xD;
          -  Have an appropriate washout from previously used biological DMARDs or JAKi&#xD;
&#xD;
          -  A female participant should have no child-bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent.&#xD;
&#xD;
          -  Significant psychiatric disease or substance abuse.&#xD;
&#xD;
          -  History of unilateral or bilateral vagotomy.&#xD;
&#xD;
          -  Active or latent tuberculosis&#xD;
&#xD;
          -  Known infection with human immunodeficiency virus (HIV); current acute or chronic&#xD;
             hepatitis B or hepatitis C; previous hepatitis B.&#xD;
&#xD;
          -  Currently implanted electrically active medical devices (e.g., cardiac pacemakers,&#xD;
             automatic implantable cardioverter-defibrillators).&#xD;
&#xD;
          -  Previous splenectomy&#xD;
&#xD;
          -  Any investigational small molecule drug or biological within 2 weeks or 2 half-lives&#xD;
             whichever is longer, before surgery.&#xD;
&#xD;
          -  Uncontrolled other inflammatory diseases&#xD;
&#xD;
          -  Current/recurrent infections that in the opinion of the PI risk&gt;benefit.&#xD;
&#xD;
          -  History of cancer within the past 5 years, except non-malignant skin cancer.&#xD;
&#xD;
          -  Chronic use of morphine or oxicodone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Operations Director</last_name>
    <phone>+44 (0)800 3688514</phone>
    <email>clinical@galvani.bio</email>
  </overall_contact>
  <location>
    <facility>
      <name>Greater Glasgow Health Board</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 OXH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Operations Director</last_name>
      <phone>+44 (0)800 3688514</phone>
      <email>clinical@galvani.bio</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electrical stimulation</keyword>
  <keyword>inflammation</keyword>
  <keyword>active implantable medical device</keyword>
  <keyword>Laparoscopy</keyword>
  <keyword>antirheumatic agents</keyword>
  <keyword>autonomic nervous system</keyword>
  <keyword>feasibility studies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

